Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Hematology (ASH)
American Society of Hematology (ASH)
The
American Society of Hematology
(
ASH
) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal
Blood
, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal,
Blood Advances
.
Ibrutinib plus Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma: Results of an Ongoing Phase 1/2b Study (PCYC-1119)
ASH 2015 – Multiple Myeloma
Read More ›
Intermediate-Dose Cytarabine/Mitoxantrone versus Standard-Dose Cytarabine/Daunorubicin Induction Therapy in AML Patients >60 Years: Results from the SAL 60+ Trial
ASH 2015 – Leukemia
Read More ›
CD19-Targeted 19-28z CAR-Modified T-Cells in Adult Patients with Relapsed/Refractory B-Cell ALL: Impact of MRD-Negative CR and Allogeneic Stem-Cell Transplant on Outcomes
ASH 2015 – Leukemia
Read More ›
Pembrolizumab plus Lenalidomide/Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (KEYNOTE-023)
ASH 2015 – Multiple Myeloma
Read More ›
Bortezomib/Melphalan/Prednisolone Induction Therapy Followed by Lenalidomide/Dexamethasone Consolidation and Lenalidomide Maintenance in Transplant-Ineligible Patients with Newly Diagnosed MM
ASH 2015 – Multiple Myeloma
The VISTA study demonstrated good tolerability of VMP; however, in a subsequent phase 2 trial, there was a higher rate of treatment discontinuation than expected. In this study, investigators demonstrated lowering the intensity of VMP proved to be both safe and effective for newly diagnosed multiple myeloma (NDMM).
Read More ›
Blinatumomab Treatment in Adult Patients with Relapsed/Refractory Ph+ ALL: Results from the Phase 2 ALCANTARA Trial
ASH 2015 – Leukemia
Read More ›
Final OS Analysis of Panorama 1 Trial of Panobinostat/Bortezomib/Dexamethasone in RRMM
ASH 2015 – Multiple Myeloma
Researchers present the final data for the secondary end point of overall survival across the entire study population of the phase 3 clinical trial PANORAMA 1, which evaluated panobinostat in combination with bortezomib and dexamethasone. Overall survival was not statistically significant.
Read More ›
Pembrolizumab, Pomalidomide, and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 2 Study
ASH 2015 – Multiple Myeloma
Read More ›
Long-Term Outcomes of Blinatumomab Treatment in Patients with MRD-Positive ALL
ASH 2015 – Leukemia
Read More ›
Ixazomib plus Lenalidomide/Dexamethasone Improves Survival Outcomes in RRMM: Results of the Phase 3 Tourmaline-MM1 Study
ASH 2015 – Multiple Myeloma
This phase 3 study demonstrated that the all-oral therapy of ixazomib in combination with lenalidomide/dexamethasone significantly increased median PFS without a substantial increase in overall toxicity. A similar benefit was noted in patients with high-risk cytogenetics.
Read More ›
Page 35 of 44
32
33
34
35
36
37
38
Conference Coverage Proudly Presented by
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us